{"schema_version":"secwatch.filing_event.v1","accession":"0001386570-25-000011","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.864887+00:00","generated_at":"2026-05-17T19:02:11.936867+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth","bullets":["Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.","Gross margin improved 480 bps to 65.0%; adjusted EBITDA $5.0M, up 221%.","Raises FY2025 revenue growth outlook to 22%-27% (previously 20%-25%).","Secured exclusive worldwide license for Niagen in Parkinson's therapy; NOPARK Phase III trial dosing completed, data expected 2026.","Niagen Plus available in 800+ U.S. wellness clinics (up from 475 in Dec 2024); cash $60.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001386570-25-000011","json":"https://secwatch.observer/filing/0001386570-25-000011.json","markdown":"https://secwatch.observer/filing/0001386570-25-000011.md","text":"https://secwatch.observer/filing/0001386570-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000138657025000011/0001386570-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000138657025000011/cdxc-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:02:11.936867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}